Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?

In March 2026, Pfizer and partner Valneva reported that their investigational 6‑valent OspA-based Lyme disease vaccine achieved roughly three‑quarters efficacy in a Phase 3 trial, while separate late‑stage studies in prostate and breast cancer also met key endpoints with TALZENNA and atirmociclib. Together, these trial wins highlight how Pfizer’s late‑stage pipeline is broadening beyond COVID-era products into vaccines and oncology programs that could reshape its future product mix. We’ll now look at how this Lyme disease vaccine progress and oncology momentum might influence Pfizer’s broader investment narrative and outlook.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Pfizer Investment Narrative Recap

To own Pfizer today, you need to believe its shift from COVID-era windfalls to a broader mix of vaccines and oncology can offset patent expirations and earnings pressure. The latest Lyme vaccine and cancer trial wins support that thesis but do not fully resolve near term worries about dividend coverage and revenue headwinds from drug pricing and loss of exclusivity, which remain the key swing factors for the stock.

Among recent updates, the TALAPRO 3 Phase 3 success for TALZENNA plus XTANDI in prostate cancer looks especially relevant. It reinforces Pfizer’s effort to build a durable oncology franchise that can help counter the looming patent cliff and soften the impact of pricing and policy pressure. Together with the Lyme vaccine data, it adds to the sense that near term catalysts are coming more from the pipeline than from cost cuts or buybacks.

Yet, despite this progress, investors should still be aware that Pfizer’s high dividend is currently stretching its cash generation and that...

Read the full narrative on Pfizer (it's free!)

Pfizer's narrative projects $59.6 billion revenue and $12.8 billion earnings by 2028.

Uncover how Pfizer's forecasts yield a $29.08 fair value, a 5% upside to its current price.

Exploring Other PerspectivesPFE 1-Year Stock Price Chart

Some of the lowest ranked analysts were expecting Pfizer’s revenue to shrink about 6.7% a year to roughly US$50.8 billion by 2029, which shows how differently you and other investors might weigh this new vaccine and oncology progress against concerns that pipeline wins may still fall short of replacing aging blockbusters.

Explore 26 other fair value estimates on Pfizer - why the stock might be worth over 2x more than the current price!

Story Continues

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

A great starting point for your Pfizer research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision. Our free Pfizer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pfizer's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 26 companies in the world exploring or producing it. Find the list for free. Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. Find 61 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include PFE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments